This talk will focus on the one of the 5 key priorities that were identified from a Union convened stakeholders meeting, on the need to generate the evidence to improve access to inhaler medicines. Barriers identified in this meeting, included lack of locally relevant data, especially on the health economic arguments for improving access to quality assured asthma medicines for all. The talk will use Africa as a case study, but highlighting some of the current work being done to address these evidence gaps both on the epidemiologic data, but as well as the health economic evidence.
GAN gratefully acknowledges funding from the University of Auckland and Wellcome (Grant number 203919/Z/16/Z) as well as sponsorship from AstraZeneca and GlaxoSmithKline that has helped to make the GAN Symposium 2024 possible. We thank the speakers and the organisations they represent for their contributions including securing their own funding to enable their participation. The Symposium programme was developed independently by the GAN Steering Group.
Our network has been targeted by an email scam. If you receive any unusual requests for assistance from any of the steering group members, please ignore it.
These emails are a common scam that has also targeted many other organisations. Please note we will never make any request for financial assistance from our collaborators. If you have any questions please contact us at info@globalasthmanetwork.org